Daewoong Pharma Receives IND Approval for Phase 3 Trial of Fexuclue for Gastric Ulcer, Limited Stock Impact
Daewoong Pharma has received approval from the Korean MFDS for a multinational phase 3 clinical trial to add a gastric ulcer treatment indication for its existing domestic 34th new drug, Fexuclue.
The trial will involve 384 patients over 21 months, aiming to demonstrate non-inferiority compared to an active control.
While successful label expansion could boost sales, the early clinical stage limits short-term stock impact, and investors should consider clinical risks.
[AI Summary]Daewoong Pharma's IND approval for Fexuclue's new indication is a positive sign for drug value expansion, but given the statistical 10% success rate for clinical trials, the short-term stock impact is limited and requires long-term monitoring.
KOSPI Filing Information
Major Management Matters Related to Investment Decision (Approval of Phase 3 Clinical Trial Plan (IND) for Additional Indication of Fexuclue Tablet (Treatment Therapy for Gastric Ulcer))